source
- Dutch regulators probe Biogen over exclusive MS test for Tysabri patientsDutch competition authority (ACM) has opened an investigation into Biogen concerning its handling of a blood test linked to its multiple sclerosis drug Tysabri. The probe focuses on whether Biogen…
- PepGen reports promising early results for myotonic dystrophy type 1 drug in six-patient trialPepGen announced that its experimental therapy for myotonic dystrophy type 1 showed the most encouraging early data yet in a small study. The trial involved six patients who received the drug for 1…